Sergio Altamura

List of Publications by Year in Descending Order

39 papers	2,990 citations	29 h-index	39 g-index
39 ext. papers	3,094 ext. citations	5.4 avg, IF	3.76 L-index

#	Paper	IF	Citations
39	Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. *Journal of*	8.3	56
38	Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo-propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4429-35	2.9	25
37	Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4422-8	2.9	26
36	Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. *Journal of Molecular Biology*, **2009**, 390, 1048-59	6.5	16
35	Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. *Journal of Medicinal Chemistry*, **2009**, 52, 6782-9	8.3	47
34	Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 5217-27	8.3	38
33	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. *Journal of Medicinal Chemistry*, **2008**, 51, 2350-3	8.3	54
32	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1814-9	2.9	83
31	2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 6083-7	2.9	45
30	A series of novel, potent, and selective histone deacetylase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5948-52	2.9	65
29	2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. *Journal of Medicinal Chemistry*, **2006**, 49, 1693-705	8.3	81
28	Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. *Journal of Medicinal Chemistry*, **2005**, 48, 4547-57	8.3	99
27	HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. *Antiviral Chemistry and Chemotherapy*, **2005**, 16, 225-45	3.5	52
26	Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. *Journal of Biological Chemistry*, **2005**, 280, 29765-70	5.4	139
25	Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. *Journal of Virology*, **2004**, 78, 13306-14	6.6	119
24	Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. *Journal of Virology*, **2004**, 78, 938-46	6.6	118
23	The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 3257-61	2.9	50

22	HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. *Journal of Medicinal Chemistry*, **2004**, 47, 5336-9	8.3	96
21	Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. *Journal of Medicinal Chemistry*, **2004**, 47, 14-7	8.3	128
20	Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. *Journal of Biological Chemistry*, **2003**, 278, 49164-70	5.4	284
19	Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. *Antiviral Research*, **2003**, 58, 1-16	10.8	172
18	Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling. *Journal of Medicinal Chemistry*, **2003**, 46, 345-8	8.3	37
17	Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. *Journal of Virology*, **2003**, 77, 13225-31	6.6	189
16	In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. *Journal of Virology*, **2003**, 77, 3669-79	6.6	109
15	A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 701-4	2.9	144
14	A scintillation proximity active site binding assay for the hepatitis C virus serine protease. *Analytical Biochemistry*, **2002**, 307, 99-104	3.1	3
13	Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. *Biochemistry*, **2002**, 41, 5483-92	3.2	44
12	Optimization of the Paregion of peptide inhibitors of hepatitis C virus NS3/4A protease. *Biochemistry*, **2000**, 39, 12898-906	3.2	37
11	Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. *Journal of General Virology*, **2000**, 81, 759-67	4.9	64
10	A high-throughput radiometric assay for hepatitis C virus NS3 protease. *Analytical Biochemistry*, **1999**, 266, 192-7	3.1	15
9	Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. *Biochemistry*, **1998**, 37, 8906-14	3.2	163
8	Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. *Circulation*, **1998**, 98, 2370-6	16.7	265
7	RNA-dependent RNA polymerase of hepatitis C virus. *Methods in Enzymology*, **1996**, 275, 58-67	1.7	54
6	Antibiotic sensitivity of the ribosomes of the ultra-thermophilic archaebacterium Pyrococcus woesei. *FEMS Microbiology Letters*, **1990**, 70, 285-290	2.9	
5	Aminoglycoside-induced mistranslation in thermophilic archaebacteria. *Molecular Genetics and Genomics*, **1988**, 214, 48-54		14

4	Probing the Evolution of the Translation Apparatus with Archaebacterial Ribosomes **1988**, 181-194		
3	Unique antibiotic sensitivity of an in vitro polypeptide synthesis system from the archaebacterium Thermoplasma acidophilum. Phylogenetic implications. *Molecular Genetics and Genomics*, **1987**, 207, 385-394		8
2	Differential features of ribosomes and of poly(U)-programmed cell-free systems derived from sulphur-dependent archaebacterial species. *FEBS Journal*, **1986**, 157, 455-62		45
1	Archaebacterial and eukaryotic ribosomal subunits can form active hybrid ribosomes. *FEBS Letters*, **1986**, 204, 129-33	3.8	6